Overview

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Status:
Unknown status
Trial end date:
2019-02-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Anticoagulants
Apixaban
Dabigatran
Rivaroxaban
Warfarin